Geron Corporation has enrolled the first patient in the Phase I clinical trial of GRNOPC1, human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury.
Pre-clinical studies have demonstrated that GRNOPC1 significantly improved kinematic scores and locomotor activity in animal models with spinal cord injuries.
The study is designed to evaluate the safety and tolerability of GRNOPC1 in patients with complete American Spinal Injury Association impairment scale grade A thoracic spinal cord injuries.
The participants in the study are expected to receive GRNOPC1 within 14 days of their injury.
Spinal cord injuries affect about 12,000 people in the US each year.
Share this article
